Guggenheim Initiates Coverage On Korsana Biosciences with Buy Rating, Announces Price Target of $70

Guggenheim analyst Yatin Suneja has initiated coverage on Korsana Biosciences (NASDAQ: KRSA) with a Buy rating. The firm has set a price target of $70 for the stock.